

1 **Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with**
2 **the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2**
3 **study**

4
5 Prof. Dr. Sue Ann Costa Clemens,^{1,2} Dr. Eveline Pipolo Milan,³ Dr Eduardo Sprinz,⁴ Dr José
6 Cerbino Neto,⁵ Dr. Filippo Pacciarini,⁶ Dr. Ping Li,⁶ Dr. Hui-Ling Chen,⁶ Dr. Igor
7 Smolenov,⁶ Prof. Dr. Andrew Pollard,¹ Dr. Ralf Clemens⁷

- 8
9 1. Oxford Vaccine Group, Department of Pediatrics, University of Oxford, and the NIHR
10 Oxford Biomedical Research Centre, Oxford, United Kingdom
11 2. Siena University, Siena, Italy
12 3. Centro de Estudos e Pesquisa em Moléstias Infecciosas Ltda. (CEPCLIN), Natal, Brazil
13 4. Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
14 5. D'Or Institute for Research and Education, Rio de Janeiro, Brazil
15 6. Clover Biopharmaceuticals Inc., Cambridge, MA, USA.
16 7. International Vaccine Institute, Seoul, Republic of Korea

17 **ABSTRACT**

18 **Background:** Ongoing outbreaks of COVID-19 are driven by waning immunity following
19 primary immunizations and emergence of new SARS-CoV-2 variants which escape vaccine-
20 induced neutralizing antibodies. It has been suggested that heterologous boosters could
21 enhance and potentially maintain population immunity.

22 **Methods:** We assessed immunogenicity and reactogenicity of booster doses of different
23 formulations of alum-adjuvanted SCB-2019 vaccine (9 µg SCB-2019 with or without CpG-
24 1018 adjuvant, or 30 µg SCB-2019 with CpG-1018) in Brazilian adults primed with
25 ChAdOx1-S vector vaccine. S-protein antibodies and ACE2-binding inhibition were
26 measured by ELISA on Days 1, 15 and 29. Participants self-reported solicited adverse events
27 and reactions.

28 **Results:** All SCB-2019 formulations increased S-protein ELISA antibodies and ACE2
29 binding inhibition to a greater extent than ChAdOx1-S. After 30 µg SCB-2019+CpG+alum
30 titers against wild-type S-protein were significantly higher than after ChAdOx1-S on Days 15
31 and 29, as were titers of neutralizing antibodies against wild-type strain and Beta, Gamma,
32 Delta, and Omicron variants. Boosting with SCB-2019 or ChAdOx1-S was well tolerated
33 with no vaccine-related serious or severe adverse events.

34 **Conclusions:** Boosting ChAdOx1-S-primed adults with SCB-2019 induced higher levels of
35 antibodies against a wild-type strain and SARS-CoV-2 variants than a homologous
36 ChAdOx1-S booster, highest responses being with the 30 µg SCB-2019+CpG+alum
37 formulation.

38 **KEYWORDS**

39 COVID-19; vaccine; booster; heterologous; homologous, SCB-2019; ChAdOx1-S

40 **Registered on ClinicalTrials.gov, NCT 05087368**

41 **Conflict of Interest statement**

42 FP, PL, IE, H-LC, and IS are all full-time employees of the study sponsor. SACC and RC are
43 scientific advisors to the study sponsor. EPM, ES, JCN and AP declare they have no conflicts
44 to declare. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts
45 of Interest and conflicts that the editor considers relevant to the content of the manuscript
46 have been disclosed.

47

48 **Funding statement**

49 The study was sponsored by Clover Biopharmaceuticals Inc. and was supported by grant
50 from Bill & Melinda Gates Foundation (BMGF), No. INV-030336.

51

52 **Corresponding Author**

53 Dr. Ralf Clemens,
54 International Vaccine Institute,
55 SNU Research Park,
56 1 Gwanak-ro,
57 Gwanak-gu,
58 Seoul,
59 08826 Korea
60 E-mail: clemens.ralf@outlook.com

61

62 **INTRODUCTION**

63 The COVID-19 pandemic has been ongoing for two years, during which time large
64 proportions of high-income country populations have achieved vaccine-induced immunity
65 following national immunization campaigns [1]. However, new variants of the wild-type
66 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from Wuhan have continued
67 to emerge each displaying new mutations of the Spike protein (S-protein) [2]. As the S-
68 protein is the main antigenic target of most of the authorized vaccines, the accumulating
69 mutations have resulted in these new variants becoming successively less susceptible to the
70 neutralizing immunity induced by the first immunization campaigns [3–7]. This has resulted
71 in new waves of pandemic COVID-19 outbreaks, most notably associated with the Beta
72 (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants [8]. The
73 efficacy of authorized vaccines against infection has been seen to decrease with each new
74 variant, both due to waning immunity following immunization and the changes in the
75 antigenic target, while protection against severe disease is largely preserved.

76 This has led to the implementation of further immunization campaigns with booster doses of
77 vaccines to broaden the immune response. Early indications are that heterologous boosters
78 are mostly more effective than homologous boosters [9–11]. Most data on such immunity has
79 been obtained with the mRNA vaccines which were the first to be authorized for use in
80 immunization campaigns and have been widely used in high-income countries. However,
81 many low- and middle-income countries are still in the phase of implementing full primary
82 immunization of their populations, with widespread use of viral vector (e.g., ChAdOx1-S1;
83 AstraZeneca, United Kingdom) or inactivated (e.g., CoronaVac; Sinovac Biotech, China)
84 vaccines. Clover Biopharmaceuticals has developed a recombinant SARS-CoV-2 S-protein
85 vaccine (S-Trimer), SCB-2019, that has been stabilized in the native pre-fusion trimeric
86 conformation using the company's proprietary Trimer-Tag[®] technology and adjuvanted with

87 the toll-like receptor 9 (TLR 9) agonist CpG-1018 and alum. The SPECTRA phase 2/3
88 efficacy trial demonstrated that two 30 µg doses of SCB-2019 had 67.2% (95.72% CI: 54.3–
89 76.8) efficacy against any COVID-19, and specific efficacies (with 95% CI) of 78.7% (57.3–
90 90.4), 91.8% (44.9–99.8) and 58.6% (13.3–81.5) against Delta, Gamma and Mu variants,
91 respectively [12]. The present study was conducted to investigate use of SCB-2019 in
92 heterologous booster regimens compared with homologous boosters in individuals who have
93 received a two-dose primary vaccination series of the adenovirus-vector vaccine, ChAdOx1-
94 S, which was authorized in Brazil. We assessed safety and immunogenicity of different
95 formulations of SCB-2019; low dose (9 µg) SCB-2019 and alum, with and without the CpG-
96 1018 adjuvant to investigate possible dose-sparing, and the standard 30 µg dose formulated
97 with CpG-1018 and alum used in the SPECTRA efficacy trial. These were given as a
98 heterologous booster in persons primed with two doses of ChAdOx1-S and responses
99 compared with a dose of ChAdOx1-S given as a homologous booster.

100 **METHODS**

101 This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three
102 sites in Brazil: Hospital de Clínicas de Porto Alegre, Hospital Gloria D'or, Rio de Janeiro and
103 Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN), Natal. The study
104 protocol was approved by each hospital's Ethical Review committee and conducted
105 according to the Declaration of Helsinki and Council for International Organizations of
106 Medical Sciences International ethical guidelines and ICH GCP guidelines. The protocol was
107 registered on ClinicalTrials.gov, registration number NCT 05087368. Participants supplied
108 written informed consent at enrolment. The objective reported here was to select the optimal
109 SCB-2019 formulation to use in the heterologous boosting of individuals primed with two
110 doses of ChAdOx1-S1-S vaccine. Selection was to be based on the safety and
111 immunogenicity, and potential impact on supply of the chosen formulation, i.e. dose-sparing.

112 ***Participants***

113 Eligible participants were male or female adults, ≥ 18 years of age who had previously
114 received two doses of ChAdOx1-S1-S vaccine 6 months (± 4 weeks) before enrolment and
115 were willing and able to comply with study requirements, including all scheduled visits,
116 vaccinations, laboratory tests, and other study procedures. Inclusion criteria included being
117 healthy or having a pre-existing but stable medical condition at the screening examination,
118 the main exclusion criterion being any previous laboratory-confirmed SARS-CoV-2
119 infection.

120 ***Vaccine***

121 The investigational SCB-2019 vaccine was supplied in a 1.0-mL pre-filled syringe containing
122 720 μg SCB-2019. Adjuvants were CpG-1018 (Dynavax Technologies) presented in a 2.0 ml
123 vial containing 12 mg/mL of a 22-mer phosphorothioate oligodeoxynucleotide in Tris
124 buffered saline (24 mg per vial), and aluminium hydroxide (Alhydrogel®, Croda Health
125 Care) supplied in vials of 10 mg/mL. The final vaccine formulations per dose contained
126 either 30 μg SCB-2019 with 1.5 mg CpG-1018 and 0.75 mg alum in a 0.5 mL volume, as
127 used in the reported efficacy trial [12], 9 μg SCB-2019 with 0.225 mg alum in a 0.15 mL
128 dose, or 9 μg SCB-2019 with 0.45 mg CpG-1018 and 0.225 mg alum in a 0.15 mL volume.
129 The comparator vaccine (ChAdOx1-S1-S) was Fiocruz COVID-19 vaccine (Rio de Janeiro,
130 Brazil) containing a Chimpanzee Adenovirus (ChadOx1) encoding the SARS-CoV-2 Spike
131 glycoprotein, with not less than 2.5×10^8 infectious units (Inf.U) in each 0.5 ml dose. These
132 vaccine formulations were prepared on the day of use by trained unblinded vaccine
133 administrators who administered them by intramuscular injection in the upper deltoid of the
134 non-dominant arm. For accurate administration of the 0.15 mL volume 1 mL tuberculin
135 syringes (Precisionglide, Becton Dickenson) were used. These vaccine administrators played

136 no further part in the study and all other study staff and the investigators and participants
137 were masked to which vaccine had been given.

138 ***Procedures***

139 At enrolment participants were randomly allocated 1:1:1:1 using a block size of 8 to four
140 equal groups to receive a third dose of ChAdOx1-S1 or a dose of one of the three
141 formulations of SCB-2019. At their first study visit on Day 1, after providing their baseline
142 blood sample, participants received their assigned vaccination and were monitored for 30
143 minutes for any immediate reactions. Using diary cards they then recorded for 7 days the
144 occurrence of solicited local reactions (pain, erythema and swelling at the injection site) and
145 systemic adverse events (fatigue, headache, myalgia, arthralgia, loss of appetite, nausea,
146 chills, fever [axillary temperature $\geq 38^{\circ}\text{C}$]) daily, together with any unsolicited adverse
147 events, serious adverse events (SAE) or medically attended adverse events (MAAE)
148 occurring up to the third study visit on Day 29. At this study visit the investigator assessed
149 any reported AE as mild (no interference with daily activities), moderate (interferes with
150 daily activities) or severe (prevents daily activity) and the relationship to the study
151 procedures.

152 ***Immunogenicity***

153 Serum samples obtained on Day 1 (before vaccination) and at the second (Day 15) and third
154 (Day 29) visits were used to assess immune responses. The primary endpoint was the
155 response assessed by ELISA as IgG antibodies against SCB-2019 S-protein on Days 15 [12].
156 Inhibition of binding of S-protein to the human angiotensin converting enzyme 2 (ACE2) was
157 measured using a competitive ELISA with SCB-2019. Additional exploratory analyses
158 included virus neutralizing activity (VNA) titers measured on Days 1, 15 and 29 in a

159 microneutralization assay (MN₅₀) against the prototype Wuhan strain and the Beta (B.1.351),
160 Delta (B.1.617.2), Gamma (P.1) and Omicron (B.1.1.529) variants of SARS-CoV-2.

161 *Statistics*

162 There was no formal hypothesis tested in this first stage of the study, all results being
163 presented and analyzed descriptively. The sample size was considered adequate for the
164 purposes of down-selection of formulation. The primary immunogenicity endpoint was
165 ELISA antibody titers against SCB-2019 S-protein expressed as geometric mean titers
166 (GMT), geometric mean-fold rise in titers over baseline (GMFR) and seroconversion rates
167 (SCR) on Days 15 and 29 in all participants who received the correct vaccination and had no
168 major protocol deviation reported or suffered a COVID-19 infection prior to blood draw.
169 Seroconversion was defined as a ≥ 4 -fold increase in post-vaccination titer in those with a
170 baseline titer above the lower limit of quantitation (LLOQ), or a post-vaccination titer ≥ 4 -
171 fold the LLOQ in those with no detectable activity at baseline. Comparisons between groups
172 were made by ANCOVA model with vaccine group as a fixed variable, baseline antibody
173 result and site as covariates. Immunogenicity results against the different SARS-CoV-2
174 variants are also expressed as GMTs, GMFR and SCR for group and variant. GMTs of
175 neutralizing antibodies against prototype strain ELISA GMTs against SCB-2019 S-protein
176 are presented in IU/mL, GMTs of neutralizing antibodies against variants and ACE2 are
177 expressed in reciprocal units. Safety data is presented descriptively as proportions of groups
178 (percentage) reporting any solicited reaction or adverse event or unsolicited adverse events.

179

180 **RESULTS**

181 Recruitment began on November 26, 2021 and the last volunteer was enrolled on March 7,
182 2022. During this period there was a major outbreak of Omicron infections. Of 144

183 volunteers screened a total of 120 volunteers were enrolled and randomized to the four study
184 groups (**Figure 1**). Only two enrolled participants did not complete through visit 3; one was
185 lost to follow-up from Group 1 after visit 1 and the second was lost to follow-up from Group
186 2 after visit 2. All of the remaining 118 randomized participants completed through visit 3,
187 except for one from Group 1 who did not provide blood for immunology assessment.
188 Demographics in the four study groups were comparable (**Table 1**). Over the course of the
189 study there were 30 suspected cases of COVID-19 in the study population, 26 of which were
190 confirmed by RT-PCR and 2 by rapid antigen test (RAT). These occurred in all four study
191 groups with onset from 8 to 77 days after vaccination (**Table 1**). Three cases had onset before
192 Day 15, and a further ten before Day 29, the remaining 17 having onset after visit 3. The
193 participants with confirmed COVID-19 infection before the second blood sample were
194 excluded from the relevant immunogenicity analyses.

195 ***Immunogenicity***

196 Vaccination in any of the four study groups resulted in increases in titers of binding
197 antibodies against SCB-2019 and inhibition of S-protein binding to ACE2 which were
198 notably higher in Groups 1–3 which received the heterologous SCB-2019 formulation than
199 Group 4 after a homologous ChAdOx1-S booster (**Figure 2**). Following the SCB-2019
200 boosters these increases were apparently dose dependent; in Groups 1 and 2 which received 9
201 µg SCB-2019 the respective GMFR from Day 1 were 9 and 11 at Day 15 and 8 and 9 at Day
202 29, while in Group 3 the GMFR were 18 and 16 at Days 15 and 29 suggesting the 30 µg
203 SCB-2019 dose was more effective in inducing a booster response (**Figure 2A**). Notably, all
204 three SCB-2019 groups elicited significantly higher GMFR than the four-fold increase
205 elicited by the homologous ChAdOx1-S booster vaccination at Day 15. The response
206 increased further in Group 4 at Day 29, but the significant difference persisted between
207 Groups 3 and 4.

208 A similar profile was observed when measuring ACE2 binding (**Figure 2B**) with higher fold-
209 increases in all groups at Days 15 and 29 than with the S-protein assay, which were still dose
210 dependent in the SCB-2019 groups. This immune response was significantly higher in
211 Groups 2 and 3 than in Group 4, the ChAdOx1-S-boosted group and this significant
212 difference persisted at Day 29 when all four groups displayed higher titers with GMFR
213 ranging from 23 to 34 in the three SCB-2019 groups compared with a GMFR of 12 in the
214 ChAdOx1-S group.

215 When assessed for neutralizing activity against the prototype strain and the different SARS-
216 CoV-2 variants at Day 15 these differences between different doses of SCB-2019 and
217 between SCB-2019 and ChAdOx1-S were still evident (**Figure 3**). All groups displayed
218 neutralizing activity against all five variants at baseline, the highest responses being against
219 the prototype Wuhan virus and the lowest against the most recent variant, Omicron
220 (B.1.1529). Two weeks after vaccination there were marked increases against all five variants
221 in all four groups, with significantly higher increases after heterologous SCB-2019 doses in
222 Groups 2 and 3 than the homologous ChAdOx1-S dose in Group 4. Overall, the biggest
223 increases in SCB-2019 groups were against prototype virus with GMFR ranging from 10 to
224 15 (**Table 2**) and Delta variant (GMFR 9 to 17), and lowest against Omicron with GMFR
225 ranging from 4 to 6. The GMFR in Group 4, after a booster ChAdOx1-S vaccination, ranged
226 from 2 to 5 for the different variants. When the GMTs of each group vs Group 4 were
227 compared the responses in Groups 2 and 3 were significantly higher than Group 4 against all
228 variants (**Figure 3**). Similarly, seroconversion rates for each variant were highest with the 30
229 μg SCB-2019 formulation, with a notably higher response against Omicron than the
230 homologous ChAdOx1-S booster (**Table 2**). Interestingly, the significant differences between
231 Groups 2 and 4, the low-dose fully adjuvanted SCB-2019 and ChAdOx1-S, did not persist to

232 Day 29 except for the Gamma variant. This was due in equal parts to waning titers in Group 2
233 and increasing titers in Group 4.

234 *Safety*

235 Overall, all four vaccine formulations were well tolerated, with no vaccine-related serious or
236 severe adverse events, no withdrawals due to an AE and no deaths (**Table 3**). The only
237 reported SAE was a leg fracture which was not related to the study procedures. One female
238 participant with a history of hypertension and prior COVID-19 infection reported a mild
239 allergic reaction 13 days after vaccination which resolved but was repeated 5 days later. The
240 investigator considered the first occurrence to be related to the study vaccine, but not the
241 second.

242 There were no clinically meaningful differences in rates of solicited local reactions between
243 the groups. Rates were highest in Group 2 (41%) and Group 3 (47%), after 9 µg and 30 µg
244 SCB-2019 with CpG and alum, respectively. The rate was lower (29%) in Group 1 who
245 received 9 µg SCB-2019 with alum alone. After the homologous ChAdOx1-S vaccination
246 33% of Group 4 reported a local reaction. Local reactions in all four groups mainly consisted
247 of mild pain at the injection site with a few cases described as moderate but none as severe
248 (**Figure 4**). Solicited systemic AEs were most frequently reported after the ChAdOx1-S in
249 Group 4 (63%), with lower rates (39% to 43%) in the SCB-2019 groups. The most frequent
250 solicited systemic AEs were headache, fatigue and myalgia (**Figure 4**), which were mainly
251 mild and transient, with no severe cases reported. As with local reactions there were no
252 clinically meaningful differences in systemic AEs between groups. There were no AESIs or
253 severe unsolicited AEs reported over the course of the study.

254 As noted, there were 30 cases of COVID-19 reported, including 13 from Day 1 to Day 29
255 when immunogenicity was assessed. Of these 25 were considered to be mild and 5 as

256 moderate in severity; no cases were described as severe or had associated pneumonia or
257 required hospitalization.

258

259 **DISCUSSION**

260 This study is the first investigation of boosting immune responses with Clover's recombinant
261 SARS-CoV-2 S-trimer fusion protein vaccine (SCB-2019) as a heterologous vaccine to the
262 primary vaccine. This study also investigated the use of a lower dose of SCB-2019, with and
263 without the CpG-1018 adjuvant, to allow for dose-sparing. The data show that the best
264 booster response in participants primed with two doses of the adenoviral vector vaccine,
265 ChAdOx1-S, was provided by the standard formulation containing 30 µg SCB-2019 with the
266 toll-like receptor 9 agonist CpG-1018 and alum. This formulation demonstrated 67.2%
267 efficacy against COVID-19 of any severity in the SPECTRA study and 100% efficacy
268 against severe disease [12]. As a heterologous booster it was not associated with any safety
269 concerns and had acceptable reactogenicity, comparable to that observed in the SPECTRA
270 study following primary immunizations [12]. The 30 µg SCB-2019 dose elicited significantly
271 higher immunity against the two key antigenic targets, measured as antibodies against SARS-
272 CoV-2 S-protein and inhibition of the binding of S-protein to the ACE2 receptor, than the
273 homologous ChAdOx1-S vaccine. Further, neutralizing antibody responses against four of
274 the major SARS-CoV-2 variants were significantly higher than with the homologous
275 ChAdOx1-S vaccine. These observations are important as ChAdOx1-S has been shown to be
276 highly protective against severe disease and death since its global roll out.

277 One exception was the level of neutralizing activity against the Omicron variant; although
278 significantly lower 15 days after homologous boosting than with heterologous with SCB-
279 2019+CpG+alum formulations, titers against Omicron were comparable at Day 29. This was

280 partly due to a continuing increase in these titers in the ChAdOx1-S group while they waned
281 slightly in the SCB-2019 groups. The question of whether this indicates a difference in the
282 kinetics of the response to the homologous booster requires further investigation. It has
283 previously been observed that the immune response to a heterologous second vaccination
284 using mRNA vaccines after a primary dose of ChAdOx1-S is more rapid than the
285 homologous vaccination, but we are unaware of similar observations with a protein or
286 inactivated vaccine [13].

287 The COVID-19 pandemic has decreased in severity but has endured in numbers of infections
288 with the appearance of new variants which despite appearing to be less sensitive to vaccine-
289 induced immunity, are also leading to less severe forms of disease with fewer hospitalizations
290 and deaths [14]. However, SARS-CoV-2 remains a threat to global health, and the experience
291 of a series of novel variants emerging and rapidly predominating in circulation highlights the
292 potential for future outbreaks. In a situation analogous to influenza, in a population that now
293 has immune experience due to infection or vaccination, future variants may lead to seasonal
294 outbreaks. For that reason, it is essential that high levels of immunity are maintained in global
295 populations to ensure there are no more explosive outbreaks of serious illness such as those
296 the world has recently experienced [15].

297 Many countries have already achieved high levels of immunity, notably those high-income
298 countries that were able to initiate mass immunization campaigns with the first vaccines to be
299 authorized, mainly the mRNA and vector vaccines targeting the S-protein of the prototype
300 virus [1]. Middle- and low-income countries are now playing catch-up, typically using less
301 expensive and more easily managed inactivated vaccines. However, the steady emergence of
302 a series of novel variants, the majority of which have changes in the main antigenic target,
303 the S-protein, has seen a decline in the extent of protective immunity afforded by the initial
304 vaccines [3–8]. The combination of waning antibodies and lower immunity against the novel

305 variant has caused resurgence of COVID-19 outbreaks around the world, which may be
306 countered by use of booster vaccinations [16]. Unfortunately, boosters only provide a
307 temporary solution as waning immunity and emergence of new escape variants means that
308 the added protection will be short-lived.

309 Evidence so far suggests that in most cases boosting with a heterologous vaccine is more
310 effective than homologous boosters [17–19] which this report appears to confirm with the
311 heterologous SCB-2019 booster eliciting higher immunity than a dose of the heterologous
312 ChAdOx1-S vaccine. In view of the global need for more COVID-19 vaccines we also
313 assessed the effect of a reduced dose of SCB-2019 to allow dose-sparing as well as omitting
314 the CpG-1018 adjuvant, which may also be dose-limiting. Our results suggest that both
315 formulations of SCB-2019 with CpG and alum containing 9 µg or 30 µg doses, provide an
316 important boost in immunity with no evidence of increased reactogenicity.

317 This is a small study with several limitations as a consequence, but the trends are
318 confirmation of other observations. Several studies have shown that heterologous booster
319 vaccination can heighten and broaden the immune response compared with homologous
320 booster doses [17–19]. We restricted this study to one priming vaccine, ChAdOx1-S, but
321 results need to be confirmed with other vaccines, particularly mRNA and inactivated
322 vaccines. We only assessed the immune responses out to four weeks after the booster
323 vaccination, and persistence of any improved immune responses following the heterologous
324 and homologous boosters will have to be assessed. Finally, we did not assess the efficacy of
325 the booster immunization; although there were several cases of COVID-19 reported in this
326 small study population it was not designed to include an efficacy assessment which would
327 also require a placebo group. Notably, none of these cases were severe and there were no
328 hospitalizations due to COVID-19.

329 In conclusion, the formulation of 30 µg SCB-2019 adjuvanted with CpG-1018 and alum is
330 safe and well tolerated and as a heterologous booster vaccine in those previously primed with
331 ChAdOx1-S and is immunologically more effective than that same vaccine given as a
332 homologous booster.
333

334 **ACKNOWLEDGEMENTS**

335 The authors wish to thank all participants and our co-investigators Drs. Tannyth Gomes dos
336 Santos, Karla Cristina Marques Afonso Ferreira de Souza, and Deyvison Soares da Costa at
337 CEPCLIN, Natal; Drs. Thaina Garbino, Larisse Longo, and Caroline Portela at Hospital de
338 Clínicas de Porto Alegre, Porto Alegre; and Drs. Bruno Pereira Stuchi, Luciana Gomes Pedro
339 Brandão, and Marcellus Dias da Costa at Hospital Glória D'or, Rio de Janeiro for their
340 invaluable contribution to this study. We are grateful to all the personnel at Vismederi SRL
341 (Siena, Italy) for their expertise in performing the immunogenicity assays, to the staff at
342 Smerud Medical Research (Oslo, Norway) for data management, and to Intriads (São Paulo,
343 Brazil) for their conduct of the study. The ChAdOx1-S vaccine used in the study was
344 generously provided by the Ministry of Health (Brasília, Brazil). The authors are grateful to
345 Keith Veitch (keithveitch communications, Amsterdam, the Netherlands) for assistance with
346 preparation and editorial management of the manuscript.

347 **REFERENCES**

- 348 1. Our World in Data. Coronavirus (COVID-19) vaccinations. Apr 24, 2021.
349 <https://ourworldindata.org/covid-vaccinations> Accessed on April 24, 2022.
- 350 2. Candido KL, Eich CR, de Fariña LO, et al. Spike protein of SARS-CoV-2 variants: a
351 brief review and practical implications. *Braz J Microbiol* 2022 Apr 9;1–25.
- 352 3. Murano K, Guo Y, Siomi H. The emergence of SARS-CoV-2 variants threatens to
353 decrease the efficacy of neutralizing antibodies and vaccines. *Biochem Soc Trans* 2021;
354 49:2879-90.
- 355 4. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19
356 vaccine against the B.1.351 variant. *N Engl J Med* 2021; 384:1885–98.
- 357 5. V. Shinde S, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine
358 against the B.1.351 variant. *N Engl J Med* 2021; 384:1899–1909.
- 359 6. Noor R, Shareen S, Billah M. COVID-19 vaccines: their effectiveness against the
360 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging
361 variants. *Bull Natl Res Cent* 2022; 46:96.
- 362 7. Keegan LT, Truelove S, Lessler J. Analysis of vaccine effectiveness against COVID-19
363 and the emergence of Delta and other Variants of Concern in Utah. *JAMA Network*
364 *Open* 2021; 4:e2140906.
- 365 8. Alcantara LCJ, Nogueira E, Shuab G, et al. SARS-CoV-2 epidemic in Brazil: how
366 variants displacement have driven distinct epidemic waves. *Virus Res* 2022; 198785.
367 Online ahead of print DOI: 10.1016/j.virusres.2022.198785.
- 368 9. Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous
369 ChAdOx1-BNT162b2 vaccination. *Nature* 2021; 600:701–6.
- 370 10. Groß R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2
371 prime-boost vaccination elicits potent neutralizing antibody responses and T cell
372 reactivity against prevalent SARS-CoV-2 variants. *EBioMedicine* 2022; 75:103761.
- 373 11. Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and
374 heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale
375 prospective cohort study. *Lancet Glob Health* 2022 Published Online April 23, 2022
376 [https://doi.org/10.1016/S2214-109X\(22\)00112-7](https://doi.org/10.1016/S2214-109X(22)00112-7)

- 377 12. Bravo L, Smolenov I, Han HH, et al. Efficacy of the adjuvanted subunit protein
378 COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised,
379 placebo-controlled trial. *Lancet* 2022; 399:461–72.
- 380 13. Markewitz R, Juhl D, Paiuli D, et al. Kinetics of the antibody response to boosting
381 with three different vaccines against SARS-CoV-2. *Front Immunol* 2022; 13:811020.
- 382 14. Wrenn JO, Pakal SB, Vestal G, et al. COVID-19 severity from Omicron and Delta
383 SARS-CoV-2 variants. *Influenza Other Respir Viruses* 2022 Online ahead of print Apr
384 13. doi: 10.1111/irv.12982.
- 385 15. Soraci L, Lattanzio F, Soraci G, et al. COVID-19 vaccines: current and future
386 perspectives. *Vaccines (Basel)* 2022; 10:608.
- 387 16. Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and
388 side-effects of boosters: a prospective community study from the ZOE COVID Study.
389 *Lancet Infect Dis* 2022 Online ahead of print Apr 8;S1473-3099(22)00146-3.
- 390 17. Hayashi JY, Simizo A, Miyamoto JG, et al. Humoral and cellular responses to
391 vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose
392 with BNT162b2. *J Infect Dis* 2022; Online ahead of print Feb 27;S0163-
393 4453(22)00115-3. doi: 10.1016/j.jinf.2022.02.026.
- 394 18. Cohen G, Jungsomsri P, Sangwongwanich J, et al. Immunogenicity and reactogenicity
395 after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19
396 (AZD1222) vaccines. *Hum Vaccin Immunother* 2022 Online ahead of print Mar 24;1-
397 7. doi: 10.1080/21645515.2022.2052525.
- 398 19. Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19
399 vaccine schedules—To mix or not to mix? *Lancet Infect Dis* 2022; 22:P438–40.

400

Table 1. Demographics of the participants in the Full Analysis Set (FAS).

Characteristics	Group 1	Group 2	Group 3	Group 4
	9 µg SCB-2019 + alum	9 µg SCB-2019 + CpG + alum	30 µg SCB-2019 + CpG + alum	ChAdOx1-S
	N = 30	N = 29	N = 32	N = 29
Sex, n (%)				
Male	15 (50)	12 (41)	12 (38)	13 (45)
Female	15 (50)	17 (59)	20 (63)	16 (55)
Mean age ± SD, yr	43.4 ± 14.4	40.0 ± 13.6	39.8 ± 12.1	36.8 ± 12.7
(Range)	(20, 66)	(21, 63)	(22, 63)	(21, 64)
Race, n (%)				
American Indian/Alaskan native	0 (0)	0 (0)	0 (0)	1 (3)
Black or African American	1 (3)	4 (14)	2 (6)	4 (14)
White	25 (83)	22 (76)	25 (78)	21 (72)
Other	2 (7)	3 (10)	4 (13)	2 (7)
Unknown/not reported	2 (7)	0 (0)	1 (3)	1 (3)
Ethnic group, n (%)				
Hispanic or Latino	21 (70)	26 (90)	20 (63)	19 (66)
Not Hispanic or Latino	2 (7)	1 (3)	9 (28)	4 (14)
Unknown/not reported	7 (23)	2 (7)	3 (9)	6 (21)
Mean body mass index ± SD, kg/m²	28.5 (4.9)	28.9 (6.4)	27.5 (5.6)	27.8 (6.5)
(Range)	(19.8, 37.9)	(17.3, 42.3)	(18.3, 46.3)	(20.0, 44.5)
Risk of severe COVID-19^a, n (%)				
Low	18 (60)	18 (62)	24 (75)	21 (72)
High	12 (40)	11 (38)	8 (25)	8 (28)
COVID-19 infections during the study, n (%)				
Time from vaccination, Mean ± SD, days	32.4 ± 12.0	44.3 ± 14.6	24.0 ± 8.2	43.2 ± 23.2
(Range)	(8, 47)	(32, 67)	(13, 37)	(8, 47)

a. Risk due to presence of known co-morbidities

Table 2: Geometric mean-fold rises (GMFR) at Days 15 and Day 29 from Day 0, and seroconversion rates (SCR) on Days 15 and 29 for antibodies against the prototype SARS-CoV-2 and four variants measured by microneutralization test (MNT₅₀).

Day	Booster vaccine	Group 1 9 µg SCIB-2019 + alum	Group 2 9 µg SCIB-2019 + CpG + alum	Group 3 30 µg SCIB-2019 + CpG + alum	Group 4 ChAdOx1-S
PROTOTYPE SARS-CoV-2					
15	n	24	25	25	25
	GMFR (95% CI)	10 (6–17)	17 (10–30)	15 (9–27)	4 (3–7)
	SCR (95% CI)	79% (58–93)	84% (64–96)	84% (64–96)	48% (28–69)
29	n	22	24	19	23
	GMFR (95% CI)	5 (3–7)	6 (4–11)	13 (7–23)	3 (2–6)
	SCR (95% CI)	64% (41–83)	71% (49–87)	84% (60–97)	39% (20–62)
BETA variant					
15	n	24	25	25	25
	GMFR (95% CI)	7 (5–12)	10 (6–18)	11 (7–20)	5 (3–7)
	SCR (95% CI)	75% (53–90)	76% (55–91)	80% (59–93)	52% (31–72)
29	n	22	24	19	23
	GMFR (95% CI)	6 (4–9)	10 (6–17)	12 (7–20)	6 (3–12)
	SCR (95% CI)	68% (45–86)	83% (63–95)	90% (67–99)	61% (39–80)
GAMMA variant					
15	n	24	25	25	25
	GMFR (95% CI)	11 (7–18)	14 (8–25)	15 (8–28)	5 (3–9)
	SCR (95% CI)	79% (58–93)	84% (64–96)	80% (59–93)	56% (35–76)
29	n	22	24	19	23
	GMFR (95% CI)	6 (4–9)	8 (5–13)	13 (7–25)	4 (2–7)
	SCR (95% CI)	68% (45–86)	75% (53–90)	79% (54–94)	44% (23–66)
DELTA variant					
15	n	24	25	25	25
	GMFR (95% CI)	9 (5–14)	11 (6–19)	17 (10–27)	5 (3–8)
	SCR (95% CI)	75% (53–90)	76% (55–91)	88% (69–98)	56% (35–76)
29	n	22	24	19	23
	GMFR (95% CI)	6 (4–11)	7 (4–13)	16 (10–27)	5 (2–9)
	SCR (95% CI)	68% (45–86)	75% (53–90)	90% (67–99)	48% (27–69)
OMICRON variant					
15	n	24	25	25	25
	GMFR (95% CI)	4 (2–6)	4 (3–7)	6 (4–10)	2 (1–4)
	SCR (95% CI)	50% (29–71)	64% (43–82)	68% (47–85)	20% (6.8–41)
29	n	22	24	19	23
	GMFR (95% CI)	4 (2–6)	4 (2–6)	5 (3–8)	5 (2–9)
	SCR (95% CI)	55% (32–76)	58% (37–78)	58% (34–80)	52% (31–73)

Seroconversion defined as a four-fold increase in titer over baseline at Day 1 or from LLoQ if Day 1 titer was < LLoQ.

GMFR = Geometric mean fold rise from Day 1 at Day 15 or Day 29

Table 3. Reactogenicity in the 29 days after the booster doses of vaccines as indicated in the Safety population.

	Group 1	Group 2	Group 3	Group 4
Vaccine	9 µg SCB-2019 + alum	9 µg SCB-2019 + CpG + alum	30 µg SCB-2019 + CpG + alum	ChAdOx1-S
	N = 30	N = 29	N = 32	N = 29
Any solicited local AE	8/28 (29%)	11/27 (41%)	14/30 (47%)	9/27 (33%)
Mild	7/28 (25%)	11/27 (41%)	13/30 (43%)	8/27 (30%)
Moderate	1/28 (4%)	0/27 (0%)	1/30 (3%)	1/27 (4%)
Any solicited systemic AE	11/28 (39%)	14/27 (52%)	13/30 (43%)	17/27 (63%)
Mild	9/28 (32%)	10/27 (37%)	7/30 (23%)	13/27 (48%)
Moderate	2/28 (7%)	4/27 (15%)	6/30 (20%)	4/27 (15%)
Any unsolicited AE				
Any SOC	10 (33%)	19 (66%)	16 (50%)	11 (38%)
Grade 3 related	0	0	0	0
Grade 3 not related	0	1	0	0
Serious adverse events (SAE)				
Any	0	1 (3%)*	0	0
Related	0	0	0	0
Medically attended AE (MAAE)	5 (17%)	7 (24%)	9 (28%)	6 (21%)
AE of special interest (AESI), AE leading to early withdrawal, or death	0	0	0	0

* One participant suffered a leg fracture which was considered to be unrelated to the study.

Figure legends

Figure 1. Study flow chart showing the disposition of the participants to each of the four groups.

Figure 2. Booster vaccination responses shown as geometric mean titers (95% CI) of ELISA antibodies against SCB-2019 (panel **A**) and ACE2 (panel **B**) at Days 15 and 29 after vaccination. Geometric mean-fold rises (GMFR) from Day 1 (95% CI) are shown with ANCOVA p values of differences between Groups 1-3 (SCB-2019) and Group 4 (ChAdOx1-S): * $p < 0.05$; ** $p < 0.01$, *** $p < 0.001$). Numbers in columns are n values per group.

Figure 3. Booster vaccination responses shown as geometric mean neutralizing titers (with 95% CI) against the indicated SARS-CoV-2 variants 15 days after vaccination. Differences in GMTs of Groups 1-3 vs. Group 4 at Day 15 were tested by ANCOVA; * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.

Figure 4. Solicited local reactions and systemic adverse events occurring within 7 days of vaccination by severity reported as percentages of each group.

Figure 1




Figure 2.




Figure 3.




Figure 4.

